Deubiquitinating enzymes: Promising targets for drug resistance.
Apoptosis
DNA repair
Deubiquitinating enzymes
Drug resistance
Signaling pathways
Therapeutic targets
Transcription factors
Journal
Drug discovery today
ISSN: 1878-5832
Titre abrégé: Drug Discov Today
Pays: England
ID NLM: 9604391
Informations de publication
Date de publication:
09 2022
09 2022
Historique:
received:
03
02
2022
revised:
05
05
2022
accepted:
22
06
2022
pubmed:
28
6
2022
medline:
31
8
2022
entrez:
27
6
2022
Statut:
ppublish
Résumé
Drug resistance to chemotherapy and molecularly targeted therapies is a current challenge in cancer treatments. The underlying mechanisms of resistance to cytotoxic chemotherapeutics and to drugs that target a specific molecule are not understood completely. In recent years, emerging evidence has frequently suggested that the dysregulation of deubiquitinating enzymes (DUBs) plays important roles in the development of drug resistance. We focus on the molecular mechanisms through which DUBs enable cancer cells to escape cell death and survive when exposed to a variety of anti-cancer drugs. Furthermore, this review summarizes the potential application of DUB inhibitors in combination therapies to overcome drug resistance.
Identifiants
pubmed: 35760282
pii: S1359-6446(22)00279-3
doi: 10.1016/j.drudis.2022.06.009
pii:
doi:
Substances chimiques
Antineoplastic Agents
0
Deubiquitinating Enzymes
EC 3.4.19.12
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2603-2613Informations de copyright
Copyright © 2022 Elsevier Ltd. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interests The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.